Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Achieve Life Sciences Inc
(NQ:
ACHV
)
11.62
USD
+0.20 (+1.75%)
Official Closing Price
Updated: 6:13 PM EST, Mar 1, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Achieve Life Sciences Inc
< Previous
1
2
Next >
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
March 13, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
March 12, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
March 03, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
February 06, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
January 13, 2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), University of Bristol, and Oracle Corporation (NYSE: ORCL) today announced the outcome of a study using Oracle's high-performance cloud infrastructure to...
From
PR Newswire
Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
December 19, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
December 17, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
December 09, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
November 06, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
October 31, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
October 24, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
From
PR Newswire
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
September 30, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
September 13, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
September 05, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the...
From
PR Newswire
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
September 04, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
August 08, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an...
From
PR Newswire
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update
August 08, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an...
From
PR Newswire
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
July 30, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
July 23, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center...
From
PR Newswire
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
June 21, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has...
From
PR Newswire
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
June 11, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline...
From
PR Newswire
Achieve Receives $4.2 Million from Exercise of Warrants
June 03, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 30, 2019
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
May 15, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an...
From
PR Newswire
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
May 07, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
April 23, 2019
Topline data from ORCA-1 trial expected in the Second Quarter of 2019
From
PR Newswire
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
April 02, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
April 01, 2019
Topline data from ORCA-1 trial expected in the Second Quarter of 2019
From
PR Newswire
Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
March 17, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...
From
PR Newswire
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
March 14, 2019
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an...
From
PR Newswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.